An Active Trend of Immunotherapy Combination Regimen as Second-Line Therapy Towards Advanced Biliary Tract Cancer by Haimin Weng, Pengfei Zeng, Yuemiao Chen, Qi Xu, Jieer Ying

Get full text

Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD‐1 and VEGF, in Chinese Patients With Advanced Solid Tumors by Fenghua Wang, Xiaoli Wei, Yulong Zheng, Jing Wang, Jieer Ying, Xiaozhong Chen, Suxia Luo, Huiyan Luo, Xufang Yu, Benchao Chen, Lei Ma, Ruihua Xu

Get full text

Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial by Jingjing Li, Shurui Zhou, Xiaoqing Xu, Qinhong Zheng, Fabiao Zhang, Cong Luo, Da Li, Xing Sun, Zhe Han, Wei Wu, Junrong Yan, Yang Shao, Yuhua Zhang, Bingchen Wu, Qing Wei, Xinbao Wang, Yiwen Zhou, Weijing Sun, Qi Xu, Jieer Ying

Get full text

Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers by Jiaojiao Ni, Chaoqun Li, Xiaoqing Xu, Qi Xu, Qian Yin, Hanlin Chen, Shurui Zhou, Jingjing Li, Qinhong Zheng, Yanru Xie, Hongjun Hua, Jianying Jin, Tieming Xie, Haiping Zhao, Feng Yan, Junjun Shen, Yihui Huang, Wangye Zheng, Junrong Yan, Xiaoying Wu, Song Wang, Qiuxiang Ou, Yang Shao, Wei Wu, Wei Zhuo, Jieer Ying

Get full text